MEPDF: AI 评分 49/100 — AI 分析 (4月 2026)

Medipal Holdings Corporation operates in the prescription pharmaceutical wholesale business in Japan. The company procures healthcare products, cosmetics, daily necessities, and OTC pharmaceuticals, serving hospitals, clinics, pharmacies, and other retail outlets.

Key Facts: AI Score: 49/100 Sector: Healthcare

公司概况

概要：

Medipal Holdings Corporation, a Japanese healthcare distribution company, focuses on prescription pharmaceuticals, medical supplies, and OTC products. With a wide distribution network serving hospitals, clinics, and retail outlets, Medipal leverages its established infrastructure and diversified product portfolio to maintain its market position in Japan's healthcare sector.

MEPDF是做什么的？

Founded in 1898 and headquartered in Tokyo, Japan, Medipal Holdings Corporation has evolved into a major player in the Japanese healthcare distribution market. Originally known as Mediceo Paltac Holdings Co., Ltd., the company rebranded to Medipal Holdings Corporation in 2009. Medipal's core business revolves around the wholesale of prescription pharmaceuticals, sourcing healthcare products related to diagnostics, testing, treatment, and administration. These include medical equipment, medical materials, and clinical diagnostic reagents. Beyond pharmaceuticals, Medipal diversifies its offerings by wholesaling cosmetics, daily necessities, and OTC pharmaceuticals. It also handles PMS (Post-Marketing Surveillance) services on contract for manufacturers and invests in orphan drugs. The company serves a broad range of customers, including hospitals, clinics, dispensing pharmacies, drugstores, home centers, convenience stores, supermarkets, discount stores, animal hospitals, livestock and fishery businesses, and processed food manufacturers. Medipal is also involved in contract-based epidemiological studies, clinical studies, and the creation of computerized medical supply databases. They also offer health insurance claims reviews, medical coding dispatch, outsourcing, and remote education activities. The company operates distribution centers and provides commissioned delivery and worker dispatch services.

MEPDF的投资论点是什么？

Medipal Holdings Corporation presents a stable investment profile within the Japanese healthcare distribution sector. The company's established presence and diversified product portfolio, including pharmaceuticals, medical supplies, and OTC products, provide a resilient revenue base. With a P/E ratio of 14.12 and a dividend yield of 2.24% as of 2026-03-17, Medipal offers a blend of value and income. A low beta of 0.39 suggests lower volatility compared to the broader market. Growth catalysts include expanding services in contract-based epidemiological studies and clinical studies. However, the may be worth researching relatively low profit margin of 1.1% and gross margin of 6.9%, indicating potential challenges in profitability. The company's ongoing investments in orphan drugs and expansion of its service offerings could drive future growth.

MEPDF在哪个行业运营？

Medipal Holdings Corporation operates within the Japanese healthcare distribution industry, a sector characterized by stringent regulations and a focus on efficient supply chain management. The industry is influenced by Japan's aging population and increasing healthcare needs. Competition includes companies like Alfresa Holdings Corporation (ALFRY), Toho Holdings (AMFPF), and Suzuken Co., Ltd. (ANSLF). Medipal's diversified product portfolio and established distribution network position it to capitalize on the growing demand for healthcare products and services in Japan.

Medical - Distribution

Healthcare

MEPDF有哪些增长机遇？

Expansion of Contract-Based Services: Medipal's involvement in contract-based epidemiological and clinical studies represents a significant growth opportunity. As healthcare research and development intensifies, the demand for outsourced research services is expected to rise. By leveraging its expertise and infrastructure, Medipal can capture a larger share of this market, estimated to reach $10 billion by 2030, with a focus on personalized medicine and preventative healthcare.
Investment in Orphan Drugs: Medipal's strategic investments in orphan drugs present a high-growth potential. Orphan drugs, which target rare diseases, often command premium pricing and benefit from regulatory incentives. The global orphan drug market is projected to reach $383 billion by 2034. Medipal can capitalize on this trend by identifying and investing in promising orphan drug candidates, potentially generating substantial returns.
Digitalization of Healthcare Supply Chain: The increasing adoption of digital technologies in healthcare supply chain management offers Medipal opportunities to enhance efficiency and reduce costs. By implementing advanced inventory management systems, data analytics, and e-commerce platforms, Medipal can optimize its operations and improve customer service. The market for digital healthcare supply chain solutions is expected to reach $40 billion by 2028.
Geographic Expansion within Japan: While Medipal has a strong presence in Japan, there are opportunities to further expand its geographic reach within the country. By targeting underserved regions and establishing new distribution centers, Medipal can increase its market share and cater to a wider customer base. The Japanese healthcare market is highly fragmented, presenting opportunities for consolidation and expansion.
Diversification into Animal Health Products: Medipal's involvement in the wholesale of animal health products for companion animals represents a diversification strategy with growth potential. The pet care market in Japan is experiencing steady growth, driven by increasing pet ownership and a focus on pet health and well-being. Medipal can expand its product offerings and distribution channels to capture a larger share of this market, projected to reach $15 billion by 2027.

Market capitalization of $3.89 billion indicates a substantial presence in the healthcare distribution market.
P/E ratio of 14.12 suggests a reasonable valuation compared to earnings.
Dividend yield of 2.24% provides a steady income stream for investors.
Low beta of 0.39 indicates lower volatility compared to the overall market.
Gross margin of 6.9% reflects the competitive dynamics of the wholesale distribution business.

MEPDF提供哪些产品和服务？

Wholesale of prescription pharmaceuticals to hospitals, clinics, and pharmacies.
Distribution of medical equipment, materials, and clinical diagnostic reagents.
Wholesale of cosmetics, daily necessities, and OTC pharmaceuticals.
Distribution of animal health products for companion animals.
Supply of food processing raw materials for agriculture, fisheries, and livestock.
Provision of contract-based epidemiological and clinical study services.
Creation of computerized medical supply databases for medical facilities.
Offer health insurance claims reviews, medical coding dispatch, and outsourcing services.

MEPDF如何赚钱？

Procures healthcare products and other goods from manufacturers.
Distributes these products through its network of distribution centers.
Generates revenue through wholesale sales to hospitals, clinics, pharmacies, and other retailers.
Provides value-added services such as PMS services and contract-based research.

Hospitals and clinics.
Dispensing pharmacies.
Drugstores, home centers, convenience stores, supermarkets, and discount stores.
Animal hospitals.
Livestock and fishery businesses.
Processed food manufacturers.

Established distribution network in Japan.
Diversified product portfolio across pharmaceuticals, medical supplies, and consumer goods.
Long-standing relationships with manufacturers and customers.
Expertise in healthcare supply chain management.

什么因素可能推动MEPDF股价上涨？

Ongoing: Expansion of contract-based epidemiological and clinical study services, driven by increasing demand for outsourced research.
Ongoing: Investments in orphan drugs, potentially leading to high-growth opportunities and premium pricing.
Upcoming: Implementation of digital technologies to improve supply chain efficiency, expected to reduce costs and enhance customer service by 2027.
Ongoing: Geographic expansion within Japan to underserved regions, aiming to increase market share.
Ongoing: Diversification into animal health products, capitalizing on the growing pet care market in Japan.

MEPDF的主要风险是什么？

Ongoing: Intense competition from other pharmaceutical wholesalers, potentially impacting market share and profitability.
Potential: Pricing pressures from healthcare providers and government regulations, potentially reducing revenue and margins.
Potential: Disruptions in the supply chain due to unforeseen events, such as natural disasters or pandemics.
Potential: Changes in healthcare policies and reimbursement rates, potentially affecting the demand for certain products and services.
Ongoing: Limited financial disclosure on the OTC market increases investment risk.

MEPDF的核心优势是什么？

Established presence in the Japanese healthcare distribution market.
Diversified product portfolio reduces reliance on any single product category.
Extensive distribution network provides broad market access.
Long-standing relationships with key suppliers and customers.

MEPDF的劣势是什么？

Relatively low profit margin compared to industry peers.
Dependence on the Japanese market exposes it to local economic conditions.
Limited international presence restricts growth opportunities.
Exposure to regulatory changes in the healthcare sector.

MEPDF有哪些机遇？

Expansion of contract-based research services.
Investments in orphan drugs with high-growth potential.
Adoption of digital technologies to improve supply chain efficiency.
Geographic expansion within Japan to underserved regions.

MEPDF面临哪些威胁？

Intense competition from other pharmaceutical wholesalers.
Pricing pressures from healthcare providers and government regulations.
Disruptions in the supply chain due to unforeseen events.
Changes in healthcare policies and reimbursement rates.

MEPDF的竞争对手是谁？

Alfresa Holdings Corporation — A major pharmaceutical wholesaler in Japan with a broad range of healthcare products and services. — (ALFRY)
Toho Holdings — Focuses on pharmaceutical distribution and dispensing pharmacy operations. — (AMFPF)
Suzuken Co., Ltd. — Offers pharmaceutical distribution, manufacturing, and other healthcare-related services. — (ANSLF)
Bunka Gakuen University — Unknown - Potentially misidentified peer. — (BUGDF)
Religare Enterprises Limited — Unknown - Potentially misidentified peer. — (RGEDF)

Key Metrics

MoonshotScore: 49/100

Company Profile

CEO: Shuichi Watanabe
Headquarters: Tokyo, JP
Employees: 13,075
Founded: 2019

AI Insight

AI analysis pending for MEPDF

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does MediPal Holdings Corporation do?

Medipal Holdings Corporation is a major distributor of pharmaceuticals, medical supplies, and other healthcare-related products in Japan. The company operates primarily in the wholesale sector, procuring products from manufacturers and distributing them to hospitals, clinics, pharmacies, and other retail outlets. In addition to its core distribution business, Medipal also provides contract-based research services and invests in orphan drugs. The company's diversified product portfolio and extensive distribution network position it as a key player in the Japanese healthcare market.

What do analysts say about MEPDF stock?

AI analysis is pending for MEPDF, so current analyst ratings are unavailable. Investors should monitor for updates on analyst coverage as it becomes available. Key valuation metrics to consider include the P/E ratio of 14.12, dividend yield of 2.24%, and gross margin of 6.9%. Growth considerations include the company's expansion into contract-based research services and investments in orphan drugs. The low beta of 0.39 suggests lower volatility compared to the broader market.

What are the main risks for MEPDF?

Medipal Holdings Corporation faces several risks, including intense competition from other pharmaceutical wholesalers, pricing pressures from healthcare providers and government regulations, and potential disruptions in the supply chain. As an OTC-traded stock, MEPDF also carries risks associated with limited financial disclosure and lower liquidity. Changes in healthcare policies and reimbursement rates could also affect the demand for certain products and services. Investors should carefully consider these risks before investing in MEPDF.